Primer: Jiangsu Recbio Technology (2179 HK) - Aug 2026
Jiangsu Recbio Technology is a pre-revenue biotechnology company at a critical juncture, with its lead vaccine candidates for shingles (REC610)...
94 Views
𝛼SK or SearchENTITY
Jiangsu Recbio Technology (2179 HK)
Jiangsu Recbio Technology (2179 HK)
16
Analysis
Industrials • China
Jiangsu Recbio Technology is an innovative vaccine company dedicated to the research, development, production, and commercialization of recombinant protein vaccines and related adjuvant technologies. Its pipeline includes vaccines for cervical cancer, shingles, COVID-19, influenza, and tuberculosis. The company was founded in 2012 and is headquartered in Taizhou, Jiangsu, PRC.
morex